Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Decline in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) saw a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 2,700 shares, a decline of 22.9% from the February 14th total of 3,500 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is currently 1.9 days.

Adlai Nortye Trading Down 0.1 %

Shares of NASDAQ ANL traded down $0.01 during trading on Friday, hitting $9.00. 631 shares of the company traded hands, compared to its average volume of 1,318. The firm has a fifty day moving average of $8.37. Adlai Nortye has a fifty-two week low of $7.11 and a fifty-two week high of $19.30.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Adlai Nortye in a report on Friday, January 12th.

Hedge Funds Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) by 128.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,310 shares of the company's stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.